Recombinant Human CCL22 protein

**Background of CCL22 Recombinant Protein**

CCL22 (C-C motif chemokine ligand 22), also known as macrophage-derived chemokine (MDC) or STCP-1. is a small secretory protein belonging to the CC chemokine family. It plays a critical role in immune regulation by mediating leukocyte trafficking and activation, particularly through its interaction with the chemokine receptor CCR4. CCL22 is predominantly produced by dendritic cells, macrophages, and certain epithelial cells under inflammatory or homeostatic conditions. Its primary function involves recruiting regulatory T cells (Tregs) and Th2-type lymphocytes to specific tissue sites, thereby modulating immune responses and maintaining tolerance.

Recombinant CCL22 is engineered *in vitro* using expression systems such as *E. coli* or mammalian cells, ensuring high purity and bioactivity. The protein typically retains its native structure, including conserved cysteine residues critical for forming disulfide bonds and stabilizing its tertiary structure. This recombinant form is widely utilized in research to study chemokine-receptor interactions, immune cell migration, and mechanisms underlying inflammatory diseases, autoimmune disorders, and cancer. For instance, CCL22-CCR4 axis dysregulation is implicated in tumor immune evasion, as many cancers overexpress CCL22 to attract Tregs, suppressing antitumor immunity.

Additionally, recombinant CCL22 serves as a tool for drug discovery, aiding in the development of CCR4-targeted therapies for conditions like atopic dermatitis, asthma, and lymphoma. Its role in balancing pro-inflammatory and immunosuppressive responses underscores its therapeutic potential, making it a focal point in immunology and oncology research.